LianBio announces data from phase 3 EXPLORER-CN trial of Mavacamten

LianBio announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese symptomatic obstructive hypertrophic cardiomyopathy, oHCM, patients were presented in a late-breaking science session at the European Society of Cardiology ,ESC, Congress 2023 and simultaneously published in a JAMA Cardiology paper titled, “Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.” LianBio previously announced topline data from EXPLORER-CN, with mavacamten demonstrating statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract , LVOT, peak gradient, the study’s primary endpoint. Mavacamten also demonstrated improvement across all secondary endpoints, including LVOT obstruction, clinical symptoms, and health status. The data presented at ESC 2023 and published in JAMA Cardiology continue to demonstrate robust evidence of mavacamten’s therapeutic benefit. New data published today provide additional detail showing mavacamten’s impact on reducing cardiac biomarkers associated with poor prognosis in oHCM, and improvement in biomarkers associated with cardiac structure remodeling. In addition, the study demonstrated mavacamten’s efficacy across prespecified subgroups, including beta-blocker usage, sex, age, body mass index, New York Heart Association NYHA class, and CYP2C19 metabolizer phenotype.